Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report

Cirino Botta, Antonia Consuelo Falzea, Rocco Giannicola, Antonino Mafodda, Cirino Botta, Rita Maria Agostino, Eleonora Iuliano, Roberto Maisano, Vittoria Cianci, Rita Emilena Saladino, Giovanna Bianco, Natale Daniele Calandruccio, Domenico Mazzacuva, Giovanna Orizzonte, Giorgio Restifo, Vincenzo Dattola, Pierpaolo Correale, Michele Caraglia, Umberto Aguglia

Risultato della ricerca: Articlepeer review

Abstract

Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of a patient with a metastatic bladder cancer who developed myositis signs (M) and a myasthenia-like syndrome (MLS) during treatment with pembrolizumab. The patient presented an autoimmunity-associated HLA haplotype (HLA-A*02/HLA-B*08/HLA-C*07/HLA-DRB1*03) and experienced an increase in activated CD8 T-cells along the treatment. The symptomatology regressed after pembrolizumab discontinuation and a pyridostigmine and steroids-based therapy. This is the first report of concurrent M and MLS appearance in cancer patients receiving pembrolizumab. More efforts are needed to define early the risk and the clinical meaning of irAEs in this setting.
Lingua originaleEnglish
Numero di pagine8
RivistaInternational Journal of Molecular Sciences
Volume22
Stato di pubblicazionePublished - 2021

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.1500.1503???
  • ???subjectarea.asjc.1300.1312???
  • ???subjectarea.asjc.1600.1607???
  • ???subjectarea.asjc.1700.1706???
  • ???subjectarea.asjc.1600.1606???
  • ???subjectarea.asjc.1600.1605???
  • ???subjectarea.asjc.1600.1604???

Fingerprint

Entra nei temi di ricerca di 'Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report'. Insieme formano una fingerprint unica.

Cita questo